Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 22, 2007. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The filing details a specific change in the holdings of the GlaxoSmithKline US Retirement Savings Plan ("the Plan") resulting from a fund movement on January 18, 2007:
- Previous Holdings: 17,028,609 Ordinary Share ADRs
- New Holdings: 16,854,500 Ordinary Share ADRs
- Average Price: $53.75
- Net Change: Decrease of 174,109 ADRs
Two directors, Dr. J-P Garnier and Dr. M M Slaoui, are noted as potentially interested in the shares held in this discretionary fund, similar to other employees and former employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly addresses compliance with Disclosure Rule 3.1.4R(1)(b) regarding the notification of the transaction.
Investor Verification Points
- Verify the impact of the 174,109 ADR reduction on the total share count of the US Retirement Savings Plan.
- Confirm the specific nature of the "fund movement" that triggered the change in holdings on January 18, 2007.
- Review the broader context of Director interests in the Plan to ensure full compliance with disclosure rules.